Contents
Academy · Research Writing · Medical Writing Support & CONSORT
Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence
A cross-sectional study of randomized controlled trial reports found that articles with declared professional medical writing support were rated as having adequate English by all reviewers 81% of the time, versus 48% for articles without declared support.
Professional medical writing support is assistance from a trained medical writer, credentialed and typically bound by authorship and disclosure guidelines, in drafting or structuring a clinical manuscript on behalf of the named authors, who retain full control over content, data interpretation and final approval. A cross-sectional study published in BMJ Open examined whether the declaration of such support was associated with better-reported randomized controlled trials (RCTs), assessed against the CONSORT checklist, the standard framework for complete and transparent RCT reporting. The study is relevant because incomplete trial reporting is a documented, persistent problem: key items such as the sample size calculation, randomization method and allocation concealment are frequently missing from published RCTs, and incomplete reporting can lead clinicians and systematic reviewers to overestimate or underestimate a treatment’s actual benefits and harms.
Learning objectives
- The findings of the cross-sectional comparison of medical-writing-supported and unsupported RCT articles
- Why CONSORT adherence, rather than prose quality alone, is the outcome this type of study tests
- How to interpret a declared-writing-support finding without overstating or understating its implications
Common misconceptions
- “The use of a professional medical writer chiefly improves prose, not the reporting of science.” The study’s primary comparison was adherence to the CONSORT checklist, a measure of methodological transparency rather than style; it therefore examined the completeness of trial reporting rather than a purely cosmetic outcome.
Study comparison and methods
The study drew its sample from parallel-group randomized controlled trials of pharmacological or dietary-supplement interventions published in BioMed Central journals, a publisher whose author guidelines require CONSORT-aligned reporting1. Reports without a declared acknowledgements section, together with duplicate publications, reviews and post-hoc analyses, were excluded, leaving a sample of full-text, parallel-group trials of pharmacological or supplement-based interventions suitable for a like-for-like comparison1. Each article was scored against twelve CONSORT items, each rated as completely or incompletely reported, and the analysis compared articles that declared a professional medical writer in the acknowledgements with those that did not, including a separate subanalysis restricted to industry-sponsored studies1. A logistic regression model then tested whether declared writing support predicted complete reporting of at least half of the twelve items, with publication year as a covariate; this design choice allows the comparison to account for the general improvement in reporting standards over time rather than attributing every gain to writing support1.
Measured differences between supported and unsupported articles
The clearest reported result concerns language adequacy, used in the study as one marker of overall manuscript quality: 81.1% of articles with declared medical writing support (43 of 53) were rated by every reviewer as having adequate written English, compared with 47.9% of articles without declared support (23 of 48), with non-overlapping 95% confidence intervals of 67.6% to 90.1% and 33.5% to 62.7%, respectively1. This difference persisted although the two groups had a similar proportion of corresponding authors affiliated with English-speaking countries (49.1% among supported articles and 50.4% among unsupported articles), which makes a greater use of writing support by authors from non-English-speaking countries an unlikely explanation for the difference in language quality1. This is the most informative feature of the design: by holding country of origin approximately constant across the two groups, the comparison isolates the writing-support variable rather than a confounder related to first-language status.
CONSORT adherence as the principal outcome
The CONSORT 2010 Statement sets out the minimum items that a report of a parallel-group randomized trial should include so that readers can judge the trial’s internal validity and reconstruct its design, principally sample-size justification, generation of the randomization sequence, allocation concealment and blinding status2. Its companion explanation-and-elaboration paper documents, with examples from published trials, how often each of these items is reported incompletely across the literature, which provides the background against which the twelve-item scoring system of the BMJ Open study was developed3. A Cochrane-affiliated systematic review of the effect of CONSORT on reporting completeness found that journals endorsing CONSORT in their author instructions tend to publish more completely reported trials than journals that do not, independently of the writing skill of any individual author; professional writing support can thus be regarded as one of several factors, alongside journal policy, that can improve reporting completeness7. Good publication practice guidance for industry-sponsored research, GPP3, specifically recommended involving a professional medical writer early, before first-draft writing begins, because incorporating CONSORT-complete reporting into a manuscript that has already been drafted is more difficult than building it in from the outset4.
Scope and limits of the finding
A single cross-sectional comparison of this kind cannot by itself demonstrate that engaging a medical writer causes better CONSORT adherence, because authors who seek writing support may differ in other respects from those who do not, for example in institutional resources or prior publication experience, and the study’s logistic regression adjusted only for publication year, not for these other potential confounders1. The finding does establish a measured, statistically significant association between declared writing support and higher ratings of language quality in a defined sample of trials, a pattern consistent with the broader literature on editorial peer review and reporting quality, including a Cochrane review which found that editorial peer review improves aspects of manuscript reporting and readability, although with effects that vary across journals and interventions6. Longstanding concerns about the broader cost of poor trial reporting, raised as early as a 1994 BMJ editorial describing avoidable waste from flawed and poorly reported research and reinforced by later estimates that a substantial share of biomedical research investment is lost to avoidable reporting and design problems, provide the wider context in which such comparisons of reporting quality warrant serious consideration rather than being regarded as a narrow question of writing style89.
Implications for authors and sponsors considering writing support
For an author or sponsor considering whether to engage a professional medical writer, the practical implication of this body of evidence is not that writing support guarantees a better trial report, but that it is one of a small number of concrete steps with a documented association with more complete reporting, alongside journal-level endorsement of CONSORT and structured internal review before submission17. Because the association persisted after accounting for authors’ country of origin, a reasonable working hypothesis is that much of the effect derives from a trained medical writer’s familiarity with the item-by-item requirements of CONSORT, acquired through routine work across many trial reports rather than occasional writing, rather than from English-language fluency alone1. This also implies that the timing of engagement is important: GPP3’s recommendation to involve a writer from the earliest planning stages, rather than after a full first draft exists, is consistent with treating CONSORT compliance as a structural property of the manuscript to be built in from the beginning, not as a final refinement4. Sponsors and authors who choose not to engage a professional writer may still obtain much of the same benefit by incorporating an internal CONSORT checklist review into their manuscript development process, modelled explicitly on the twelve items assessed in this type of study, rather than relying on general editorial judgement alone23. A second, often overlooked implication concerns timing within the trial lifecycle rather than only within manuscript drafting: because several CONSORT items, principally the pre-specified primary outcome and the planned sample-size calculation, depend on decisions made before a trial enrols its first participant, a writer or internal reviewer engaged only at the manuscript stage can document these items accurately only if they were properly recorded in the trial protocol and statistical analysis plan3. For this reason, registries such as ClinicalTrials.gov and the broader movement towards mandatory prospective trial registration function as a complementary safeguard alongside writing support, providing a later writer or reviewer with an independent, time-stamped record of what was planned before results existed, against which the reporting of the primary outcome and sample size in the final manuscript can be checked7. A medical writer or internal reviewer engaged early can identify a discrepancy between the registered protocol and the manuscript draft before submission, which is a materially different, and far less damaging, outcome than the discovery of the same discrepancy by a peer reviewer or a later systematic reviewer after publication, since the latter can raise questions about selective outcome reporting that identification before submission avoids6. This argument for early involvement is the strongest practical justification for the GPP3 recommendation discussed above, and it applies whether the support is provided by a dedicated professional writer or by a designated internal reviewer responsible for checking the manuscript draft against the registered protocol before submission.
Key points
Key points
A cross-sectional comparison found that RCT reports with declared professional medical writing support were rated as having adequate English considerably more often than unsupported reports (81.1% vs 47.9%), a difference that persisted after accounting for authors’ country of origin, although the design cannot demonstrate that writing support alone caused the difference.
Practical application
Practical application
- Involve a professional medical writer early rather than after the first draft is complete. Good publication practice guidance recommends this specifically because CONSORT-complete reporting is more easily built in from the outset than added retrospectively.
- Assess the draft against the 30-item CONSORT 2025 checklist before submission. Sample-size justification, randomization method, allocation concealment and blinding status should be checked explicitly, since these are the items most often reported incompletely.
- Declare any writing support transparently in the acknowledgements. Transparent declaration is both an ICMJE/GPP 2022 expectation and, according to this study’s design, part of what distinguishes a comparable, well-documented trial report.
Frequently asked questions
It directly measured ratings of language quality, which the authors used as one marker of overall manuscript quality; it did not isolate a separate measure of validity, so the finding is best interpreted as evidence about reporting quality and clarity rather than about the underlying scientific validity of the trial.
Yes; in addition to its full-sample analysis, the study conducted a subanalysis restricted to industry-sponsored studies, reflecting the more frequent use of professional medical writers in industry-sponsored than in non-industry trials.
No. The two groups had almost identical proportions of authors from English-speaking countries, around 49-50% in each, which weakens that explanation for the observed difference.
No, they are related but distinct. CONSORT items concern methodological transparency, such as randomization and allocation concealment; the study used language-quality ratings as one proxy among several reporting-quality measures it examined.
Good Publication Practice (GPP 2022) and the ICMJE Recommendations both set out transparency and disclosure expectations for medical writing support in industry-related and academic publications.
References
- Gattrell WT, Hopewell S, Young K, et al. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(6):e010329. read 10 October 2026. View on BMJ Open
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. read 10 October 2026. View on The BMJ
- Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. read 10 October 2026. View on The BMJ
- Battisti WP, Wager E, Baltzer L, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. read 10 October 2026. View on Annals of Internal Medicine
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. read 10 October 2026. View on ICMJE.org
- Jefferson T, Rudin M, Brodney Folse S, Davidoff F. Editorial peer review for improving the quality of reports of biomedical studies. Cochrane Database of Systematic Reviews. 2007;(2):MR000016. read 10 October 2026. View on Cochrane Library
- Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane systematic review. Systematic Reviews. 2012;1:60. read 10 October 2026. View on Systematic Reviews
- Altman DG. The scandal of poor medical research. BMJ. 1994;308(6924):283-284. read 10 October 2026. View on The BMJ
- Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. The Lancet. 2009;374(9683):86-89. read 10 October 2026. View on The Lancet
- Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised trials in journal and conference abstracts. The Lancet. 2008;371(9609):281-283. read 10 October 2026. View on The Lancet
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence. Pubrica. https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/
Pubrica Academy. “Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence.” Pubrica, 10 Oct. 2026, pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/.
Pubrica Academy (2026) Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence. Pubrica. Available at: https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/ (Accessed: 15 October 2026).
Pubrica Academy. “Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence.” Pubrica. October 10, 2026. https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/
Pubrica Academy, ‘Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/> accessed 15 October 2026.
Pubrica Academy. Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/
Pubrica Academy, “Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/
@misc{/la_medical_writing_support_rct_reporting_quality_2026,
author = {{Pubrica Academy}},
title = {Professional Medical Writing Support and RCT Reporting Quality: Cross-Sectional Evidence},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/research-services/cross-sectional-research-on-professional-medical-writing-support/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Medical Writing Support Disclosure & CONSORT Checklist
This checklist is intended for use before submission of a trial report drafted with professional writing assistance.
[ ] Declared the medical writer's involvement and funding source in the acknowledgements [ ] Confirmed the writer's role followed GPP 2022 and ICMJE authorship/contribution rules [ ] Scored the manuscript against all relevant CONSORT 2025 items before submission [ ] Checked sample-size calculation, randomization method, and allocation concealment are explicitly reported [ ] Verified blinding status is stated for participants, caregivers, and outcome assessors [ ] Confirmed the target journal's own CONSORT endorsement and submission requirements
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s medical writing team drafts RCT manuscripts against the CONSORT 2025 checklist from the first outline, with transparent GPP 2022-aligned disclosure of the writer’s role, so that reporting completeness is built in rather than added retrospectively.